Literature DB >> 17142862

Liver stem cells: implications for hepatocarcinogenesis.

Malcolm R Alison1.   

Abstract

Numerous studies point to the fact that liver tumors are derived from single cells (monoclonal), but the important question is, which cell? Stem cell biology and cancer are inextricably linked. In continually renewing tissues such as the intestinal mucosa and epidermis, in which a steady flux of cells occurs from the stem cell zone to the terminally differentiated cells that are imminently to be lost, it is widely accepted that cancer is a disease of stem cells, as these are the only cells that persist in the tissue for a sufficient length of time to acquire the requisite number of genetic changes for neoplastic development. In the liver the identity of the founder cells for the two major primary tumors, hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC), is more problematic. The reason for this is that no such obvious unidirectional flux occurs in the liver, though it is held that the centrilobular hepatocytes may be more differentiated (polyploid) and closer to cell senescence than those cells closest to the portal areas. Moreover the existence of bipotential hepatic progenitor cells (HPCs), along with hepatocytes endowed with longevity and long-term repopulating potential suggests there may be more than one type of carcinogen target cell. Irrespective of which target cell is involved, cell proliferation at the time of carcinogen exposure is pivotal for "fixation" of the genotoxic injury into a heritable form. Taking this view, any proliferative cell in the liver can be susceptible to neoplastic transformation. Thus, hepatocytes are implicated in many instances of HCC, direct injury to the biliary epithelium implicates cholangiocytes in some cases of CC, whereas HPC/oval cell activation accompanies very many instances of liver damage irrespective of etiology, making such cells very likely carcinogen targets. Of course, we must qualify this assertion by stating that many carcinogens are both cytotoxic and cytostatic, and that HPC proliferation may be merely a bystander effect of this toxicity. An indepth discussion of causes of cancer in the liver are beyond the scope of this review, but infectious agents (e.g., hepatitis B and C viruses) play a major role, not just in transactivating or otherwise disrupting cellular proto-oncogenes (hepatitis B virus [HBV]), but in also causing chronic inflammation (hepatitis C virus [HCV] and HBV). Sustained epithelial proliferation in a milieu rich in inflammatory cells, growth factors, and DNA-damaging agents (reactive oxygen and nitrogen species produced to fight infection), will lead to permanent genetic changes in proliferating cells. The upregulation of the transcription factor nuclear factor kappaB (NF-kappaB) in transformed hepatocytes, through the paracrine action of tumor necrosis factor-alpha from neighboring endothelia and inflammatory cells, may be critical for tumor progression given the mitogenic and anti-apoptotic properties of proteins encoded by many of NF-kappaB's target genes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 17142862     DOI: 10.1385/SCR:1:3:253

Source DB:  PubMed          Journal:  Stem Cell Rev        ISSN: 1550-8943            Impact factor:   5.739


  69 in total

1.  Hematopoietic stem cells convert into liver cells within days without fusion.

Authors:  Yoon-Young Jang; Michael I Collector; Stephen B Baylin; Anna Mae Diehl; Saul J Sharkis
Journal:  Nat Cell Biol       Date:  2004-05-09       Impact factor: 28.824

Review 2.  Hepatic stem cells: from inside and outside the liver?

Authors:  M R Alison; P Vig; F Russo; B W Bigger; E Amofah; M Themis; S Forbes
Journal:  Cell Prolif       Date:  2004-02       Impact factor: 6.831

3.  Proliferating cell nuclear antigen assessed by a computer-assisted image analysis system in patients with chronic viral hepatitis and cirrhosis.

Authors:  M F Donato; E Arosio; V Monti; P Fasani; D Prati; A Sangiovanni; G Ronchi; M Colombo
Journal:  Dig Liver Dis       Date:  2002-03       Impact factor: 4.088

4.  Combined hepatocellular and cholangiocarcinoma with marked squamous cell carcinoma components arising in non-cirrhotic liver.

Authors:  Koichi Tsuneyama; Yasuharu Kaizaki; Kenji Doden; Eiichi Kidani; Kenichi Harada; Motoko Sasaki; Yasuni Nakanuma
Journal:  Pathol Int       Date:  2003-02       Impact factor: 2.534

5.  Relation between hepatocyte G1 arrest, impaired hepatic regeneration, and fibrosis in chronic hepatitis C virus infection.

Authors:  Aileen Marshall; Simon Rushbrook; Susan E Davies; Lesley S Morris; Ian S Scott; Sarah L Vowler; Nicholas Coleman; Graeme Alexander
Journal:  Gastroenterology       Date:  2005-01       Impact factor: 22.682

6.  Structure and expression of Tg737, a putative tumor suppressor gene, in human hepatocellular carcinomas.

Authors:  C Bonura; P Paterlini-Brechot; C Brechot
Journal:  Hepatology       Date:  1999-09       Impact factor: 17.425

Review 7.  Preneoplastic lesions in human hepatocarcinogenesis.

Authors:  Louis Libbrecht; Valeer Desmet; Tania Roskams
Journal:  Liver Int       Date:  2005-02       Impact factor: 5.828

8.  Focal nodular hyperplasia with concomitant hepatocellular carcinoma: a case report and clonal analysis.

Authors:  S-H Zhang; W-M Cong; M-C Wu
Journal:  J Clin Pathol       Date:  2004-05       Impact factor: 3.411

Review 9.  The role of determined stem-cells in the cellular lineage of hepatocellular carcinoma.

Authors:  S Sell
Journal:  Int J Dev Biol       Date:  1993-03       Impact factor: 2.203

10.  Regeneration of hepatocyte 'buds' in cirrhosis from intrabiliary stem cells.

Authors:  Olga Falkowski; Hee Jung An; I Andreea Ianus; Luis Chiriboga; Herman Yee; A Brian West; Neil D Theise
Journal:  J Hepatol       Date:  2003-09       Impact factor: 25.083

View more
  74 in total

1.  Hepatitis C virus-induced cancer stem cell-like signatures in cell culture and murine tumor xenografts.

Authors:  Naushad Ali; Heba Allam; Randal May; Sripathi M Sureban; Michael S Bronze; Ted Bader; Shahid Umar; Srikant Anant; Courtney W Houchen
Journal:  J Virol       Date:  2011-09-21       Impact factor: 5.103

Review 2.  Therapeutic application of stem cells in gastroenterology: an up-date.

Authors:  Patrizia Burra; Debora Bizzaro; Rachele Ciccocioppo; Fabio Marra; Anna Chiara Piscaglia; Laura Porretti; Antonio Gasbarrini; Francesco Paolo Russo
Journal:  World J Gastroenterol       Date:  2011-09-14       Impact factor: 5.742

3.  Current research in hepatic stem-cell function.

Authors:  Neil D Theise
Journal:  Gastroenterol Hepatol (N Y)       Date:  2007-03

4.  Multiple cells of origin in cholangiocarcinoma underlie biological, epidemiological and clinical heterogeneity.

Authors:  Vincenzo Cardinale; Guido Carpino; Lola Reid; Eugenio Gaudio; Domenico Alvaro
Journal:  World J Gastrointest Oncol       Date:  2012-05-15

Review 5.  Epigenetic regulation of cancer stem cells in liver cancer: current concepts and clinical implications.

Authors:  J U Marquardt; V M Factor; S S Thorgeirsson
Journal:  J Hepatol       Date:  2010-05-31       Impact factor: 25.083

Review 6.  How do persistent infections with hepatitis C virus cause liver cancer?

Authors:  Jonathan K Mitchell; Stanley M Lemon; David R McGivern
Journal:  Curr Opin Virol       Date:  2015-09-29       Impact factor: 7.090

7.  New Approaches for Studying Alcoholic Liver Disease.

Authors:  Jun Xu; Xiao Liu; Bin Gao; Michael Karin; Hidekazu Tsukamoto; David Brenner; Tatiana Kisseleva
Journal:  Curr Pathobiol Rep       Date:  2014-09-14

Review 8.  Wnt signaling in liver cancer.

Authors:  Yutaka Takigawa; Anthony M C Brown
Journal:  Curr Drug Targets       Date:  2008-11       Impact factor: 3.465

9.  Deletion of the Met tyrosine kinase in liver progenitor oval cells increases sensitivity to apoptosis in vitro.

Authors:  Gaelle del Castillo; Valentina M Factor; Margarita Fernández; Alberto Alvarez-Barrientos; Isabel Fabregat; Snorri S Thorgeirsson; Aránzazu Sánchez
Journal:  Am J Pathol       Date:  2008-04-01       Impact factor: 4.307

10.  Mathematical modeling of therapeutic strategies for myeloid malignancies.

Authors:  Dan Wu; Huiyu Li; Wen Du; Xiaoxia Ji; Wei Liu; Shiang Huang; Yi Xiao
Journal:  Pathol Oncol Res       Date:  2012-10       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.